Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older

INTRODUCTION: A favorable benefit-risk balance is required to support licensure of biologics, in keeping with regulatory agencies’ evolving recommendations, including the United States Food and Drugs Administration. We present a structured semi-quantitative benefit-risk analysis of MenACYW-TT, a qua...

Descripción completa

Detalles Bibliográficos
Autores principales: Neveu, David, Mallett Moore, Tamala, Zambrano, Betzana, Chen, Aiying, Kürzinger, Marie-Laure, Marcelon, Lydie, Singh Dhingra, Mandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600069/
https://www.ncbi.nlm.nih.gov/pubmed/37755671
http://dx.doi.org/10.1007/s40121-023-00864-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600069/
https://www.ncbi.nlm.nih.gov/pubmed/37755671
http://dx.doi.org/10.1007/s40121-023-00864-4

Ejemplares similares